Moderna Stock Slides After Citi Downgrade Cites Valuation Risk

Moderna (NASDAQ: MRNA) shares fell more than 4% in pre-market trading after analysts at Citi downgraded the stock to Sell, citing valuation concerns after a powerful rally pushed the stock to a new 52-week high.

Citi Downgrade Flags Valuation

Citi downgraded Moderna to Sell from a previous rating, according to a research note. The bank raised its price target on the stock to $80 from a prior $60, but the new target remains significantly below the stock's recent 52-week high of $208.90, implying considerable downside for investors.

The downgrade represents a notable shift in Wall Street consensus. According to the source material, Moderna had previously carried only two sell ratings among roughly two dozen analysts covering the company, making Citi's move a meaningful change in institutional sentiment.

Legal and Pipeline Headwinds Mount

Ad

The analyst action comes amid other challenges for the biotech firm. On September 28, a Delaware federal court denied Moderna's motion to dismiss a patent infringement lawsuit filed by Bayer’s Monsanto division. This development introduces fresh legal risk and uncertainty for the company.

Furthermore, some analysts have questioned if investor enthusiasm has outpaced near-term commercial prospects for its pipeline. According to the report, analysts at Leerink and Rothschild Redburn have characterized the market’s reaction to positive data for its intismeran cancer vaccine as premature, with regulatory hurdles and a multi-year sales ramp-up still ahead before meaningful revenue can be realized.

Market Context

A lack of broad market support contributed to the decline, with the Nasdaq trading flat in the pre-market session, offering no macroeconomic tailwind to offset the company-specific selling pressure. The combination of the high-conviction downgrade and unresolved patent litigation prompted investors to reassess the stock's sharp climb from a 52-week low of $22.28.